Dr. Gray Kirby is a clinical development leader whose career spans more than two decades at the forefront of oncology research, early-phase clinical development, and patient-centered innovation. From his earliest professional roles in academic medicine and specialty pharmacy to his influential leadership positions within global pharmaceutical organizations, he has consistently shaped programs, mentored emerging professionals, and accelerated scientific discovery with a steadfast commitment to improving patient outcomes. His professional journey reflects both depth and breadth—an uncommon combination that has allowed him to contribute meaningfully at every point along the clinical research continuum.
As Director of Clinical Development in Early Oncology at AstraZeneca, Dr. Kirby provided strategic and scientific oversight for some of the organization’s most complex and high-potential investigational therapies. He was a leader in first-in-human and Phase 1–2 programs involving cutting-edge immuno-oncology and targeted agents, including, bispecifics, and multiple ADC and solid and liquid tumor candidates. His work included protocol development, clinical data interpretation, safety assessment, and cross-functional alignment across biometrics, operations, regulatory, translational science, and medical strategy. Through his leadership, several programs advanced through critical development decision points, demonstrating his ability to guide science from concept to execution with precision and sound judgment.
Dr. Kirby’s leadership foundation was shaped during his years at MedImmune and earlier at GSK, where he contributed to critical early oncology programs and served as a global study manager overseeing dose escalation and expansion trials in thoracic malignancies. His contributions during these years displayed a consistent pattern: a commitment to scientific excellence, a clear understanding of operational feasibility, and the interpersonal skill to align diverse teams behind shared objectives. Even in highly dynamic environments, he demonstrated the ability to drive studies forward while maintaining focus on data quality and patient-centered decision-making.
Beyond large pharmaceutical organizations, Dr. Kirby’s career includes extensive experience in the clinical research site and startup environment. As Vice President of Clinical Research for a national clinical trial site network, he oversaw scientific, operational, and commercial components of a 25-person division. His leadership extended across multiple therapeutic areas, and he played an instrumental role in ensuring the integrity and efficiency of site-based research operations. His entrepreneurial spirit and operational acumen were further evident in his work as founder and CEO of Carolina Physicians Research, where he led a multi-specialty clinical research center focused on delivering high-quality clinical trials to patient and training the local physician on clinical research.
Earlier in his career, Dr. Kirby’s academic and clinical foundation was built through roles at UNC, Wake Med, and within critical care pharmacy settings. His fellowship in Clinical Drug Research and Drug Development at Burroughs Wellcome, followed by a pharmacy residency in cardiology and critical care at The Ohio State University Medical Center, prepared him to approach clinical challenges with analytical depth and multidisciplinary understanding. These experiences instilled the scientific curiosity, precision, and ethical grounding that would continue to guide him throughout his professional journey.
Teaching and mentorship have remained constant threads throughout Dr. Kirby’s career. He has served an Adjunct Assistant Professor at the University of North Carolina and Affiliate Associate Professor at the University of Maryland School of Pharmacy , where he has shaped the next generation of pharmacists and clinical scientists. His leadership in PharmD fellowship and student preceptor programs underscores his belief that the future of clinical research depends on developing thoughtful, well-trained professionals who understand both the science and humanity inherent in drug development.
Dr. Kirby’s work has been recognized through multiple awards, including AstraZeneca Early Oncology Team Awards and academic honors such as Rho Chi and the UNC Public Health Scholar distinction. Yet despite such recognition, he remains grounded in his mission: to advance research that meaningfully improves the lives of patients. His participation on nonprofit boards supporting cancer patients reflects this commitment, as he continues to advocate for patient needs, community support systems, and compassionate care throughout the treatment journey.
Today, Dr. Kirby continues to contribute his expertise to organizations seeking thoughtful leadership in biotechnology, pharmaceuticals, AI-driven research, healthcare innovation, and clinical development strategy. His legacy is one of integrity, mentorship, scientific advancement, and unwavering dedication to improving patient outcomes through smarter, more compassionate research.
Character:
Dr. Kirby exemplifies character through his unwavering commitment to ethical research and patient-centered decision-making. He upholds the highest standards of integrity in every professional endeavor, ensuring that scientific rigor never overshadows human compassion. His colleagues regard him as a leader who models humility, responsibility, and respect in all interactions.
Knowledge:
His depth of knowledge spanning clinical research, oncology development, and early-phase research equips him to guide programs with insight and foresight. He combines academic expertise with decades of hands-on experience, allowing him to interpret data and risk with exceptional clarity. His ability to integrate scientific, operational, and regulatory knowledge strengthens every team and project he leads.
Strategic:
Dr. Kirby’s strategic mindset enables him to balance scientific ambition with real-world feasibility, ensuring programs advance with purpose and precision. He consistently anticipates development challenges and aligns teams around solutions that support long-term success. His strategic leadership has been instrumental in advancing first-in-human studies and innovative oncology platforms.
Communication:
A communication style that is defined by clarity, candor, and a genuine desire to uplift others. He excels at translating complex scientific concepts into accessible insights for cross-functional stakeholders. His mentorship, teaching, and team leadership are grounded in open dialogue and a deep respect for shared understanding.
